ZyVersa Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The meeting approved all five proposals, including director elections, auditor ratification, equity plan expansion, and share issuances related to warrants. Shareholders participated virtually, and final vote results will be filed in a Form 8-K.
Fiscal Year 2024
-
The conference highlighted progress on inflammation and kidney disease therapies, with IC100 advancing toward clinical trials and VAR-200 set for phase II in early 2025. Industry trends favor combination therapies for obesity-related comorbidities, and the company is actively pursuing strategic partnerships.
-
The meeting covered board introductions, four key proposals, and voting procedures. All proposals, including director election, auditor ratification, incentive plan amendment, and share issuance, were approved. Shareholders had a chance to ask questions at the end.